GLY-200 is an experimental drug that acts as a "polymeric
mucin binding
duodenal exclusion therapy"; it is developed by Glyscend Therapeutics for type 2 diabetes and obesity. It is intended to reversibly mimic the effects of
gastric bypass without the need for surgery. The drug is not absorbed into the body from the gut and has been tested as monotherapy and with
metformin.[1][2][3][4][5][6]
References
^Significant Weight Loss Due to a Novel Oral Polymeric Mucin Binding Duodenal Exclusion Therapy
Nimgaonkar, Ashish, MD; Sanglard, Larissa, MD; Habegger, Kirk, PhD; Colbert, Kevin, MS; Carlson, Taylor, PhD; et al. Obesity; Silver Spring Vol. 29, (Dec 2021): 162.
^A First-in-Human Study of GLY-200, an Oral, Gut- Restricted, Pharmacologic Duodenal Exclusion Therapy
Fineman, Mark, PhD; Bryant, Christine, PhD; Colbert, Kevin, MS; Jozefiak, Thomas, PhD; Petersen, John, PhD; et al. Obesity; Silver Spring Vol. 30, (Nov 2022): 19.
^Fineman, Mark; Bryant, Christine; Jozefiak, Thomas H.; Nimgaonkar, Ashish; Carlson, Taylor (20 June 2023). "832-P: Coadministration of Metformin with GLY-200, a Clinical-Stage Nonabsorbed Drug for the Treatment of Type 2 Diabetes (T2D), Has No Significant Impact on the Oral Absorption of Metformin in the Rat". Diabetes. 72 (Supplement_1).
doi:
10.2337/db23-832-P.
S2CID259395861.
^Nimgaonkar, Ashish; Bryant, Christine; Habegger, Kirk M.; Colbert, Kevin; Carlson, Taylor; Polomoscanik, Steven; Petersen, John S.; Jozefiak, Thomas H.; Fineman, Mark (20 June 2023). "823-P: GLY-200, a Pharmacologic Duodenal Exclusion Therapy, Improved Metabolic Parameters in the DIO Rat". Diabetes. 72 (Supplement_1).
doi:
10.2337/db23-823-P.
S2CID259423112.
GLY-200 is an experimental drug that acts as a "polymeric
mucin binding
duodenal exclusion therapy"; it is developed by Glyscend Therapeutics for type 2 diabetes and obesity. It is intended to reversibly mimic the effects of
gastric bypass without the need for surgery. The drug is not absorbed into the body from the gut and has been tested as monotherapy and with
metformin.[1][2][3][4][5][6]
References
^Significant Weight Loss Due to a Novel Oral Polymeric Mucin Binding Duodenal Exclusion Therapy
Nimgaonkar, Ashish, MD; Sanglard, Larissa, MD; Habegger, Kirk, PhD; Colbert, Kevin, MS; Carlson, Taylor, PhD; et al. Obesity; Silver Spring Vol. 29, (Dec 2021): 162.
^A First-in-Human Study of GLY-200, an Oral, Gut- Restricted, Pharmacologic Duodenal Exclusion Therapy
Fineman, Mark, PhD; Bryant, Christine, PhD; Colbert, Kevin, MS; Jozefiak, Thomas, PhD; Petersen, John, PhD; et al. Obesity; Silver Spring Vol. 30, (Nov 2022): 19.
^Fineman, Mark; Bryant, Christine; Jozefiak, Thomas H.; Nimgaonkar, Ashish; Carlson, Taylor (20 June 2023). "832-P: Coadministration of Metformin with GLY-200, a Clinical-Stage Nonabsorbed Drug for the Treatment of Type 2 Diabetes (T2D), Has No Significant Impact on the Oral Absorption of Metformin in the Rat". Diabetes. 72 (Supplement_1).
doi:
10.2337/db23-832-P.
S2CID259395861.
^Nimgaonkar, Ashish; Bryant, Christine; Habegger, Kirk M.; Colbert, Kevin; Carlson, Taylor; Polomoscanik, Steven; Petersen, John S.; Jozefiak, Thomas H.; Fineman, Mark (20 June 2023). "823-P: GLY-200, a Pharmacologic Duodenal Exclusion Therapy, Improved Metabolic Parameters in the DIO Rat". Diabetes. 72 (Supplement_1).
doi:
10.2337/db23-823-P.
S2CID259423112.